Skip to main content
Log in

Acute monocytic leukemia with histiocytic morphology in hematological remission after azacytidine and venetoclax therapy

  • Images in Hematology
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Laurencet FM, Chapuis B, Roux-Lombard P, Dayer JM, Beris P. Malignant histiocytosis in the leukaemic stage: a new entity (M5c-AML) in the FAB classification? Leukemia. 1994;8:502–6.

    CAS  PubMed  Google Scholar 

  2. Esteve J, Rozman M, Campo E, Munoz F, Urbano-Isspizua A, Rozman C. Leukemia after true histiocytic lymphoma: another type of acute monocytic leukemia with histiocytic differentiation (AML-M5c)? Leukemia. 1995;9:1389–91.

    CAS  PubMed  Google Scholar 

  3. Ru YX, Dong SX, Zhao SX, et al. Histiocytic differentiation in acute monocytic leukemia. Ultrastruct Pathol. 2016;40:18–23.

    Article  Google Scholar 

  4. Liu B, Li T. Relapsed acute monocytic leukemia presenting as histiocytic morphology. Int J Hematol. 2020;112:607–8.

    Article  Google Scholar 

  5. Boeckx N, Renard M, Uyttebroeck A. Acute monocytic leukemia with histiocytic features. Br J Haematol. 2006;137:2.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shuku Sato.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sato, S., Tamai, Y. Acute monocytic leukemia with histiocytic morphology in hematological remission after azacytidine and venetoclax therapy. Int J Hematol 115, 299–300 (2022). https://doi.org/10.1007/s12185-022-03296-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-022-03296-x

Navigation